Merck and Moderna maintain a long-standing strategic collaboration on their personalized mRNA cancer vaccine, most recently reinforced by positive Phase 3 melanoma trial results announced August 19, 2026, which drove sharp share price gains without any indication of full ownership consolidation. No regulatory filings, earnings commentary, or market rumors point to merger discussions, and the companies' established licensing and profit-sharing arrangement provides sufficient alignment for pipeline advancement. This supports the 98.4% market-implied probability against an announced deal by year-end. Tail risks include an unforeseen shift if blockbuster vaccine potential prompts Merck to seek full control via acquisition, though current fundamentals and deal precedents make such a move improbable in the near term.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於是
2% 機率
最新
最新
2026-12-31
是
2% 機率
最新
最新
2026-12-31
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a long-standing strategic collaboration on their personalized mRNA cancer vaccine, most recently reinforced by positive Phase 3 melanoma trial results announced August 19, 2026, which drove sharp share price gains without any indication of full ownership consolidation. No regulatory filings, earnings commentary, or market rumors point to merger discussions, and the companies' established licensing and profit-sharing arrangement provides sufficient alignment for pipeline advancement. This supports the 98.4% market-implied probability against an announced deal by year-end. Tail risks include an unforeseen shift if blockbuster vaccine potential prompts Merck to seek full control via acquisition, though current fundamentals and deal precedents make such a move improbable in the near term.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
市場開放時間： Aug 19, 2026, 3:58 PM ET
交易量
$411結束日期
2026-12-31市場開放時間
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a long-standing strategic collaboration on their personalized mRNA cancer vaccine, most recently reinforced by positive Phase 3 melanoma trial results announced August 19, 2026, which drove sharp share price gains without any indication of full ownership consolidation. No regulatory filings, earnings commentary, or market rumors point to merger discussions, and the companies' established licensing and profit-sharing arrangement provides sufficient alignment for pipeline advancement. This supports the 98.4% market-implied probability against an announced deal by year-end. Tail risks include an unforeseen shift if blockbuster vaccine potential prompts Merck to seek full control via acquisition, though current fundamentals and deal precedents make such a move improbable in the near term.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
交易量
$411結束日期
2026-12-31市場開放時間
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck and Moderna maintain a long-standing strategic collaboration on their personalized mRNA cancer vaccine, most recently reinforced by positive Phase 3 melanoma trial results announced August 19, 2026, which drove sharp share price gains without any indication of full ownership consolidation. No regulatory filings, earnings commentary, or market rumors point to merger discussions, and the companies' established licensing and profit-sharing arrangement provides sufficient alignment for pipeline advancement. This supports the 98.4% market-implied probability against an announced deal by year-end. Tail risks include an unforeseen shift if blockbuster vaccine potential prompts Merck to seek full control via acquisition, though current fundamentals and deal precedents make such a move improbable in the near term.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions